These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1183 related articles for article (PubMed ID: 27153395)

  • 21. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
    Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
    Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families.
    Li J; Meeks H; Feng BJ; Healey S; Thorne H; Makunin I; Ellis J; ; Campbell I; Southey M; Mitchell G; Clouston D; Kirk J; Goldgar D; Chenevix-Trench G
    J Med Genet; 2016 Jan; 53(1):34-42. PubMed ID: 26534844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-frequency actionable pathogenic exome variants in an average-risk cohort.
    Rego S; Dagan-Rosenfeld O; Zhou W; Sailani MR; Limcaoco P; Colbert E; Avina M; Wheeler J; Craig C; Salins D; Röst HL; Dunn J; McLaughlin T; Steinmetz LM; Bernstein JA; Snyder MP
    Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30487145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanding ACMG variant classification guidelines into a general framework.
    Masson E; Zou WB; Génin E; Cooper DN; Le Gac G; Fichou Y; Pu N; Rebours V; Férec C; Liao Z; Chen JM
    Hum Genomics; 2022 Aug; 16(1):31. PubMed ID: 35974416
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reclassification of
    Lee JS; Oh S; Park SK; Lee MH; Lee JW; Kim SW; Son BH; Noh DY; Lee JE; Park HL; Kim MJ; Cho SI; Lee YK; Park SS; Seong MW
    J Med Genet; 2018 Dec; 55(12):794-802. PubMed ID: 30415210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of Pathogenicity of
    Brown A; Zamanpoor M; Love DR; Prosser DO
    Sultan Qaboos Univ Med J; 2019 Nov; 19(4):e324-e334. PubMed ID: 31897316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort.
    Johnston JJ; Brennan ML; Radenbaugh B; Yoo SJ; Hernandez SM; ; Lewis KL; Katz AE; Manolio TA; Biesecker LG
    Genet Med; 2022 Mar; 24(3):736-743. PubMed ID: 34906458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consideration of Cosegregation in the Pathogenicity Classification of Genomic Variants.
    Jarvik GP; Browning BL
    Am J Hum Genet; 2016 Jun; 98(6):1077-1081. PubMed ID: 27236918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
    Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
    Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PATH-SCAN: a reporting tool for identifying clinically actionable variants.
    Daneshjou R; Zappala Z; Kukurba K; Boyle SM; Ormond KE; Klein TE; Snyder M; Bustamante CD; Altman RB; Montgomery SB
    Pac Symp Biocomput; 2014; ():229-40. PubMed ID: 24297550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel mutations in actionable breast cancer genes by targeted sequencing in an ethnically homogenous cohort.
    Akter H; Sultana N; Martuza N; Siddiqua A; Dity NJ; Rahaman MA; Samara B; Sayeed A; Basiruzzaman M; Rahman MM; Rashidul Hoq M; Amin MR; Baqui MA; Woodbury-Smith M; Uddin KMF; Islam SS; Awwal R; Berdiev BK; Uddin M
    BMC Med Genet; 2019 Sep; 20(1):150. PubMed ID: 31477031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adapting ACMG/AMP sequence variant classification guidelines for single-gene copy number variants.
    Brandt T; Sack LM; Arjona D; Tan D; Mei H; Cui H; Gao H; Bean LJH; Ankala A; Del Gaudio D; Knight Johnson A; Vincent LM; Reavey C; Lai A; Richard G; Meck JM
    Genet Med; 2020 Feb; 22(2):336-344. PubMed ID: 31534211
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.
    Seifert BA; O'Daniel JM; Amin K; Marchuk DS; Patel NM; Parker JS; Hoyle AP; Mose LE; Marron A; Hayward MC; Bizon C; Wilhelmsen KC; Evans JP; Earp HS; Sharpless NE; Hayes DN; Berg JS
    Clin Cancer Res; 2016 Aug; 22(16):4087-4094. PubMed ID: 27083775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
    Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
    JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance.
    Tsai GJ; Rañola JMO; Smith C; Garrett LT; Bergquist T; Casadei S; Bowen DJ; Shirts BH
    Genet Med; 2019 Jun; 21(6):1435-1442. PubMed ID: 30374176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
    Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
    Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exome Sequencing in a Family with Luminal-Type Breast Cancer Underpinned by Variation in the Methylation Pathway.
    van der Merwe N; Peeters AV; Pienaar FM; Bezuidenhout J; van Rensburg SJ; Kotze MJ
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28241424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data.
    van Marcke C; Collard A; Vikkula M; Duhoux FP
    Crit Rev Oncol Hematol; 2018 Dec; 132():138-144. PubMed ID: 30447919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. "Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
    Colas C; Golmard L; de Pauw A; Caputo SM; Stoppa-Lyonnet D
    Breast; 2019 Jun; 45():29-35. PubMed ID: 30822622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.